BERKELEY, CA--(Marketwired - Nov 30, 2015) - Dynavax Technologies Corporation (
Date and Time: Saturday, December 5, 2015, 5:30pm - 7:30pm EST
Abstract Title: Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN.
Session Number: 616
Session Name: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
Abstract Number: 1539
Location: Hall A, Level 2 (Orange County Convention Center)
Please click here for the full abstract. The poster presentation with updated data will be made available on or after December 5, 2015.
About SD-101
SD-101, the subject of ASH abstract 1539, is Dynavax's proprietary, second-generation, TLR 9 agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.
Contact Information:
Contact:
Michael Ostrach
Chief Financial Officer
510-665-7257